Hepatocellular carcinoma surveillance and the emerging role of biomarker-based models
In the latest Research Review Educational Series, Associate Professor Simone Strasser, a senior staff specialist at Royal Prince Alfred Hospital, Sydney, explores hepatocellular carcinoma (HCC) surveillance and the emerging role of biomarker-based models.
Strasser notes that “it was presumed that with widespread uptake of neonatal and childhood hepatitis B vaccination, effective hepatitis B antiviral therapy, and high uptakes of hepatitis C curative therapies, rates of HCC would start to decline in the community”.
However, this has not happened, due to an increase in population rates of obesity-related metabolic-associated fatty liver disease (MAFLD). This places increasing emphasis on the prevention and management of obesity and metabolic dysfunction in our battle against HCC.
To learn more about the emerging challenges in this area you can read the full article here.
Further information
You can explore the latest advances in hepatocellular carcinoma through our curated list of recent publications.
